Toxicities Associated With PD-1/PD-L1 Blockade.
Toxicities Associated With PD-1/PD-L1 Blockade.
复制标题
与PD-1/PD-L1阻滞有关的毒性。
DOI：
10.1097/ppo.0000000000000296
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Davis EJ
中科院分区：
文献类型：
--
作者：
Wang DY;Johnson DB;Davis EJ
免疫检查点抑制剂，特别是那些针对PD-1/PD-L1的免疫检查点抑制剂，在不同类型的癌症患者中产生持久的反应。虽然这些药物通常耐受性很好，但它们可以引起广泛的自身免疫性并发症，可能影响任何器官系统。这些毒性的治疗主要包括使用皮质类固醇和其他药物的免疫抑制。本文将简要讨论免疫相关不良事件的发生机制，综述PD-1/PD-L1受体阻滞剂引起的主要毒性反应的临床和病理特点，并对其处理方法进行综述。
Immune checkpoint inhibitors, particularly those targeting PD-1/PD-L1, produce durable responses in a subset of patients across cancer types. Although often well-tolerated, these agents can induce a broad spectrum of autoimmune-like complications that may affect any organ system. Treatment of these toxicities primarily consists of immune suppression with corticosteroids and other agents. This review will briefly discuss the mechanisms of immune-related adverse events (irAEs), overview the clinical and pathologic features of major toxicities caused by PD-1/PD-L1 blockade, and review their management.